Sulfoximine compound having FGFR inhibitory effect, pharmaceutical composition comprising same, and use thereof

A compound as shown in formula (I), a tautomer, a stereoisomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof:

• wherein, n and m are each independently 0, 1, 2, or 3;
• CyA is selected from the group consisting of:
• wherein denotes a bond connected to CyB, and
• denotes a bond connected to CyC;
• CyB is selected from the group consisting of:
• C6-10 aryl and 5-12 membered heteroaryl;
• CyC is selected from the group consisting of:
• C6-10 aryl, 5-12-membered heteroaryl, saturated or partially unsaturated C3-6 carbocyclyl and saturated or partially unsaturated 4-12-membered heterocyclyl;
• R1 is selected from the group consisting of:
• H, D, halogen, CN, OH, NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 alkylamino, C2-4 alkenyl, C1-4 haloalkenyl, C2-4 alkynyl, C1-4 haloalkynyl, C3-6 saturated or partially unsaturated carbocyclyl, C3-6 halogenated saturated or partially unsaturated carbocyclyl, C3-6 saturated or partially unsaturated carbocyclyl-O—, SF5 and 4-12 membered heterocyclyl;
• R2 and R3 are each independently selected from the group consisting of:
• C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 alkylamino, C3-6 saturated or partially unsaturated carbocyclyl and 4-12-membered heterocyclyl;
• wherein R2 and R3 can be the same or different;
• or R2 and R3 together with the sulfur atom to which they are connected form a 4-12-membered heterocyclyl;
• R4 is selected from the group consisting of:
• H, D, halogen, CN, OH, NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 alkylamino, C2-4 alkenyl, C1-4 haloalkenyl, C2-4 alkynyl, C1-4 haloalkynyl, C3-6 saturated or partially unsaturated carbocyclyl, C3-6 halogenated saturated or partially unsaturated carbocyclyl, C3-6 carbocyclyl-O—, SF5 and 4-12-membered heterocyclyl;
• R5 is -L-Rw, wherein L is selected from the group consisting of:
• covalent bond, —C1-4 alkyl-, —NR6—, —C1-4 alkyl NR6—;
• R6 is selected from the group consisting of:
• H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl and C1-6 haloalkoxy;
• Rw is selected from the group consisting of:
• halogen, cyano,
• and 5-12-membered nitrogen-containing heterocyclyl;
• RWA, RWB, and RWC are each independently selected from the group consisting of:
• H, D, halogen, CN, C(O)Ra, C(O)ORa, NRaRb, C(O)NRaRb, C(O)NRaORb, or selected from the group consisting of:
• C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, phenyl, 3 to 7-membered saturated or partially unsaturated heterocyclyl with 1 to 2 heteroatoms independently selected from nitrogen, oxygen and sulfur, and 5 to 6-membered heteroaryl with 1 to 4 heteroatoms independently selected from nitrogen, oxygen and sulfur;
• and the RWA, RWB, and RWC can each be independently substituted with 1, 2, or 3 substituents selected from the group consisting of:
• C1-6 alkylamino and C1-6 alkoxy;
• or R6 and Rw together form a ring;
• and the ring is selected from the group consisting of:
• 5-12 membered heteroaryl and 4-12 membered heterocyclyl;
• R7 is selected from the group consisting of:
• H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 alkylamino, C2-4 alkenyl, C1-4 haloalkenyl, C2-4 alkynyl, C1-4 haloalkynyl, C3-6 saturated or partially unsaturated carbocyclyl, C3-6 halogenated saturated or partially unsaturated carbocyclyl, C6-10 aryl, 5-12 membered heteroaryl, 4-12-membered heterocyclyl;
• or R4 and R7, as well as the atoms between them, together form a ring, and the ring is selected from the group consisting of:
• C6-8 saturated or partially unsaturated carbocyclyl, C6-10 aryl, 6-12 membered heteroaryl and 6-12 membered saturated or partially unsaturated heterocyclyl;
• R8 is selected from the group consisting of:
• H, OH, NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy and C1-6 alkylamino;
• R9 is selected from the group consisting of:
• H, D, halogen, CN, NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy and C1-6 alkylamino;
• unless otherwise specified, each of the above-mentioned alkyl, alkoxy, haloalkyl, haloalkoxy, alkylamino, alkenyl, haloalkenyl, alkynyl, haloalkynyl, saturated or partially unsaturated carbocyclyl, halogenated saturated or partially unsaturated carbocyclyl, saturated or partially unsaturated heterocyclyl, aryl and heteroaryl can be substituted with one or more Ra;
• Ra and Rb are each independently selected from H, D, halogen, CN, oxo (═O), OH, NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 alkylamino, C2-4 alkyenyl, C1-4 haloalkenyl, C2-4 alkynyl, C1-4 haloalkynyl, C3-6 saturated or partially unsaturated carbocyclyl, C3-6 halogenated saturated or partially unsaturated carbocyclyl, C3-6 saturated or partially unsaturated carbocyclyl-O—, 4-12 membered heterocyclyl;
• wherein, the heterocyclyl is a saturated or partially unsaturated non-aromatic group;
• the carbocyclyl or heterocyclyl can be optionally in the form of a monocycle, bridged ring, spirocycle, or fused ring.